NCT04273932View on ClinicalTrials.gov

Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

October 17, 2019

Primary Completion Date

June 15, 2023

Study Completion Date

August 12, 2023

Conditions
Parkinson Disease
Interventions
DRUG

Lithium

Lithium aspartate of lithium carbonate will be administered by mouth.

Trial Locations (1)

14221

University at Buffalo, Williamsville

All Listed Sponsors
lead

State University of New York at Buffalo

OTHER

NCT04273932 - Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease. | Biotech Hunter | Biotech Hunter